Today it was reported that the VP, Quality of Nevro (NYSE: NVRO), Doug Alleavitch, exercised options to buy 1,000 NVRO shares at $53.70 a share, for a total transaction value of $53.7K.
This recent transaction increases Doug Alleavitch’s holding in the company by 5.24% to a total of $1.2 million. Following Doug Alleavitch’s last NVRO Buy transaction on July 26, 2018, the stock climbed by 1.5%.
See today’s analyst top recommended stocks >>
Based on Nevro’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $96.08 million and GAAP net loss of $10.62 million. In comparison, last year the company earned revenue of $78.02 million and had a GAAP net loss of $11.61 million. Currently, Nevro has an average volume of 819.1K.
Based on 9 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $76.75, reflecting a -23.2% downside. 12 different firms, including B.Riley FBR and BMO Capital, currently also have a Buy rating on the stock.
The insider sentiment on Nevro has been positive according to 43 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nevro Corp. engages in the provision of medical devices. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
